注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Viridian Therapeutics Inc是一家专注于为患有严重疾病患者提供先进疗法的生物技术公司。该公司致力于开发VRDN-001和VRDN-002两种候选产品,以治疗患有甲状腺眼病(TED)的患者。TED是一种使人衰弱的自身免疫性疾病,会导致眼眶内的炎症和纤维化,从而导致复视、疼痛和潜在的失明。其主要候选产品VRDN-001是一种靶向胰岛素样生长因子-1受体(IGF-1R)的差异化人源化单克隆抗体,是一种经临床和商业验证的TED靶点。该公司已启动VRDN-001的I/II期临床试验。其第二种候选产品VRDN-002是一种独特的IGF-1R抗体,它结合了半衰期延长技术,旨在支持作为一种方便、低剂量的皮下注射剂,从而治疗患有TED的患者。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Victor R. Ambros | - | - | Scientific Advisory Board Member |
Jeffery D. Molkentin | - | - | Scientific Advisory Board Member |
Eva van Rooij | - | - | Scientific Advisory Board Member |
Stefanie Dimmeler | - | - | Scientific Advisory Board Member |
Arlene M. Morris | 70 | 2018 | Independent Director |
Frank Slack | - | - | Scientific Advisory Board Member |
Tomas Kiselak | 35 | 2020 | Independent Chairperson of Board |
Peter Evan Harwin | 35 | 2020 | Independent Director |
Jennifer K. Moses | 47 | 2021 | Independent Director |
Stephen F. Mahoney | 53 | 2023 | CEO, President & Director |
Sarah Gheuens | 44 | 2023 | Independent Director |
Michael R. Bristow | 79 | - | Co-Founder & Member of the Scientific Advisory Board |
Marvin H. Caruthers | 84 | - | Co-Founder & Scientific Advisory Board Member |
Eric N. Olson | - | - | Co-Founder & Chairman of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核